JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on October 6, 2004; DOI: 10.1124/jpet.104.072496


0022-3565/05/3121-339-345$20.00
JPET 312:339-345, 2005
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.104.072496v1
312/1/339    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moreb, J. S.
Right arrow Articles by Mohuczy, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moreb, J. S.
Right arrow Articles by Mohuczy, D.

CHEMOTHERAPY, ANTIBIOTICS, AND GENE THERAPY

Retinoic Acid Down-Regulates Aldehyde Dehydrogenase and Increases Cytotoxicity of 4-Hydroperoxycyclophosphamide and Acetaldehyde

Jan S. Moreb, Amir Gabr, Govind R. Vartikar, Santosh Gowda, James R. Zucali, and Dagmara Mohuczy

University of Florida, Department of Medicine, Division of Hematology/Oncology, Gainesville, Florida

Received June 10, 2004; accepted October 5, 2004.


    Abstract
 Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 
Multiple prior studies have identified aldehyde dehydrogenases (ALDH) that are capable of oxidizing retinal to retinoic acid. In this study, we test the hypothesis that the accumulation of intracellular retinoic acid may lead to the suppression of ALDH expression and thus increase cytotoxicity to 4-hydroperoxycyclophosphamide (4-HC) in vitro. Mainly A549, but also other lung cancer cell lines, were used in our experiments, with the former having high levels of two ALDH isozymes expressed. Dose-response and time-course experiments were performed by incubating the cells with all-trans retinoic acid (ATRA) as well as other commercially available retinoids. The results show that incubation of A549 cells with any of the retinoids at pharmacologic doses for ≥48 h results in a significant decrease in ALDH-1A1 and ALDH-3A1 enzyme activity and protein levels but not the corresponding mRNAs. Such a decrease in ALDH activity was seen in all cell lines tested and results in a significant increase in toxicity of 4-HC and acetaldehyde, both of which are substrates for the enzymes. Prior incubation with ATRA also results in increased cytotoxicity, although to a lesser degree, of phenylketophosphamide and melphalan, neither of which is a substrate for ALDHs. These results suggest a post-translational mechanism through which retinoids decrease both ALDH expression, which results in increased cytotoxicity of 4-HC and acetaldehyde, although other previously described effects of these retinoids may contribute to the slight increase in cytotoxicity seen with other chemotherapy agents. These results may have clinical implications in regard to the use of retinoids in lung cancer prevention and treatment.


Aldehyde dehydrogenases (ALDH) are a group of enzymes that catalyze the conversion of a broad range of aldehydes to the corresponding acid via a NAD+-dependent irreversible reaction. Two of these enzymes, cytosolic ALDH-1A1 and ALDH-3A1, have been found to be responsible for drug resistance in various tumor types against the antineoplastic drugs collectively known as oxazaphosphorines, which include cyclophosphamide and its active metabolites (Hilton, 1984Go; Manthey et al., 1990Go; Sreerama and Sladek, 1993Go; von Eitzen et al., 1994Go; Yoshida et al., 1998Go). Cyclophosphamide is a prodrug that requires cytochrome P450 hydroxylation for activation. Prior to the release of the active alkylating metabolite phosphoramide mustard, cyclophosphamide passes through an aldehyde intermediate, aldophosphamide. ALDH oxidizes aldophosphamide to the inactive metabolite carboxyphosphamide (Manthey et al., 1990Go). Several inhibitors of ALDH activity have been used to demonstrate the reversal of this drug resistance mechanism. We and others (Bunting et al., 1994Go; Bunting and Townsend, 1996Go; Magni et al., 1996Go; Moreb et al., 1996Go, 1998Go) have successfully shown that overexpression of ALDH-1A1 or ALDH-3A1 in cell lines and normal hematopoietic progenitors results in a significant increase in the resistance to the active metabolites of cyclophosphamide in vitro. Furthermore, we have shown that down-regulation of ALDH-1A1 (Moreb et al., 2000Go) and ALDH-3A1 (J. S. Moreb and M. Schweder, unpublished data) using antisense RNA results in increased sensitivity of tumor cells to 4-hydroperoxycyclophosphamide (4-HC), an active derivative of cyclophosphamide.

Multiple prior studies have identified several ALDH that are capable of oxidizing retinal to retinoic acid (RA), a modulator of gene expression and cell differentiation that maintains numerous tissues (Gudas et al., 1994Go; Means and Gudas, 1995Go; Chytil, 1996Go). Human, mouse, and rat ALDH-1A1 have been reported to have high activity for retinal oxidation (Lee et al., 1991Go; Yoshida et al., 1992Go; Bhat et al., 1995Go; Hsu et al., 1999Go). Thus, in this study, we test the hypothesis that the accumulation of intracellular retinoic acid may lead to the suppression of ALDH expression and thus increase 4-HC cytotoxicity in vitro. Our results suggest that retinoids indeed suppress levels of ALDH-1A1 and ALDH-3A1 protein and enzyme activity in physiologic and pharmacologic doses. The effects of retinoic acid on ALDH-1A1 and ALDH-3A1 provide new insight into the post-translational regulation of the enzymes.


    Materials and Methods
 Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 
Cell Lines. The A549 nonsmall cell lung cancer (NSCLC) cell line was obtained from the American Type Culture Collection (Rockville, MD). These cells were grown in RPMI 1640 culture medium supplemented with 10% fetal bovine serum (FBS) and used when in the exponential log phase of their proliferation. Other lung cancer cell lines used, including SW210.5 (small cell lung cancer) and ADLC-5M2 (NSCLC), were obtained from Dr. Gerold Bepler (H. Lee Moffitt Cancer Center, Tampa, FL) (Bepler et al., 1988Go, 1989Go).

Materials. All retinoids, all-trans RA (ATRA), and 9-cis and 13-cis retinoic acids were purchased from Sigma-Aldrich (St. Louis, MO). NAD, propionaldehyde, acetaldehyde, and melphalan were also purchased from Sigma-Aldrich. All retinoids were dissolved in ethanol. Melphalan was dissolved in small amounts of ethanol and acetic acid and then diluted in culture medium to the appropriate concentration.

4-HC and phenylketophosphamide (PKP) were supplied generously by Dr. Michael Colvin (Duke University, Durham, NC). 4-HC was dissolved in culture medium to obtain a 1-µg/µl solution. PKP was dissolved in dimethyl sulfoxide and then diluted in culture medium to obtain a 1-µg/µl final solution.

Chicken anti-human ALDH-1A1 and ALDH-3A1 polyclonal antibodies were generously provided by Dr. L. Sreerama (St. Cloud University, Minneapolis, MN) and Dr. N.E. Sladek (University of Minnesota, Minneapolis, MN). The specificity of these antibodies has been documented by Dr. Sladek's groups (Sreerama and Sladek, 1993Go; Sladek et al., 2002Go).

RA Incubations. ATRA was the main retinoic acid used throughout the experiments. The other retinoic acids were used for comparison with ATRA. A dose-response effect on ALDH enzyme activity was performed using A549 cells after a 72-h incubation with a range of ATRA concentrations of 10-10 to 10-5 M.

A time-course experiment was also performed using A549 cells and a fixed ATRA concentration of 1 µM. ALDH enzyme activity was measured after a 12-h ATRA incubation and every 24 h up to 8 days. The starting cell concentration for A549 cells was either 0.5 x 106 (up to 72-h incubations) or 0.1 x 105 cells (for longer incubations) in 15 ml of RPMI 1640 in a 75-cm2 flask. Cell count and viability were determined before any further use of the cells in the different assays. Viability was determined by the trypan blue exclusion criteria. Since ATRA is dissolved in 100% ethanol, control cultures received the same amount of ethanol as the ATRA-treated cultures in all the experiments.

Measurement of ALDH Activity. Measurement of the human ALDH activity was performed as described previously (Moreb et al., 2000Go). Briefly, cells were lysed in 0.5 to 1 ml of buffer containing 50 mM Tris (pH 8), 25 mM EDTA, 5 mM {beta}-mercaptoethanol, 1 mM phenylmethylsulfonyl fluoride, and 0.1% sarcosyl. After centrifugation at 10,000 rpm for 10 min at 4°C, the supernatant was collected and used to determine ALDH activity. The protein concentration was determined using the BioRad protein assay kit with a bovine serum albumin standard (BioRad, Hercules, CA).

Aliquots of 600 µl incubated at 37°C using the Beckman DLC 64 cuvette spectrophotometer (Beckman Coulter, Inc., Fullerton, CA) with the addition of protein extract, 5 mM NAD+, and 5 mM propionaldehyde (as substrate) were used to measure the change in absorbance at 340 nm over 5 min. A control reaction in which propionaldehyde was not added monitored the endogenous rate of NAD+ reduction.

Western Analysis. Western blot analysis was performed to demonstrate changes in the protein levels of ALDH-1A1 and ALDH-3A1. The same protein extract used for ALDH enzyme activity (described above) was used for the Western blot analysis. Equal amounts of protein from each experimental group were separated by size on a 10% denaturing SDS-polyacrylamide gel, electrotransferred onto nitrocellulose membranes, and labeled as described previously (Moreb et al., 2000Go). Chicken anti-human ALDH-1A1 and ALDH-3A1 primary antibodies were used at 1:200 dilution, and secondary antibody (horseradish peroxidase-labeled rabbit anti-chicken antibody; Sigma-Aldrich) was used at 1:6000 dilution. The chemiluminescence method (SuperSignal; Pierce, Rockford, IL) was used for the final visualization of the protein bands on X-ray film. All blots were labeled again for visualization of actin as a loading control using anti-actin antibody (Calbiochem, San Diego, CA).

Northern Analysis. Northern analysis was used to detect changes in ALDH-1A1 and ALDH-3A1 mRNAs after the incubation of cells with retinoic acid. Total RNA was extracted from A549 cells after different incubation times with ATRA using the Chomczynski and Sacchi method (Chomczynski and Sacchi, 1987Go). Total RNA (10 µg/lane) was separated on 1.2% agarose formaldehyde gel and blotted onto a nylon membrane (Micron Separations, Inc., Westboro, MA) by capillary transfer for 2 days. Detection of ALDH-1A1 and ALDH-3A1 was performed as described previously (Moreb et al., 2000Go), using random primer 32P-dCTP-labeled ALDH-1A1 and ALDH-3A1 cDNAs.

In Vitro Drug Treatment Assay. After incubation with or without retinoic acid, cells were harvested. Following the determination of cell count and viability, A549, ADLC-5M2 (1 x 105 cells/2 ml of fresh culture medium), or SW 210.5 cells (4 x 105 cells/2 ml) were treated with 4-HC (40-80 µg/ml) for 30 min at 37°C, washed twice with culture medium, and then either plated for liquid colony assay (A549 cells only) or used for LDH cytotoxicity assay (see below) to determine the 4-HC cytotoxic effects.

To determine the specificity of retinoic acid effects on ALDH and sensitivity to 4-HC, we also treated A549 cells with drugs not metabolized by ALDH-1A1 or ALDH-3A1, such as PKP and melphalan. Again, cells with or without retinoic acid preincubation were treated with the corresponding drug for 30 min (PKP) or 60 min (melphalan) at 37°C, washed twice, and used for the LDH cytotoxicity assay.

Because acetaldehyde is a carcinogen metabolized by ALDH, we examined the effect of ATRA preincubation on the acute toxicity of a 24-h exposure of A549 cells to acetaldehyde. To determine the toxic dose of acetaldehyde, we first performed a dose-response experiment with acetaldehyde using the LDH cytotoxicity assay.

Cytotoxicity Assays. The Cytotoxicity Detection Kit was purchased from Roche Diagnostics (Mannheim, Germany) and used to measure the percentage of cytotoxicity by determining LDH activity in the supernatants of treated cells. We followed the manufacturer's provided protocol. The optimal cell concentration per well and the optimal drug concentration were first determined by preliminary experiments to find the cell concentration that will give the maximal difference between the low and high controls.

A549 cells were also plated in a liquid colony assay to further measure the cytotoxic effects of 4-HC with or without retinoic acid preincubation as described previously (Moreb et al., 2000Go). After treatment, cells were resuspended in 4 ml of RPMI + 10% FBS and plated in four 35-mm Petri dishes for each experimental group. Colonies (>10 cells) adhering to the bottom of the plate were counted on day 4 using an inverted microscope. Untreated A549 cells were plated similarly at 200 cells/ml/dish. The toxicity of 4-HC was reflected by the amount of colonies killed and expressed as a percentage of total colonies recovered from equal numbers of untreated A549 cells.

Statistical Analysis. Statistical significance of the difference between experimental groups was calculated using Student's paired t test for two means. A P value of <0.05 was considered significant.


    Results
 Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 
Regulation of ALDH Expression by Retinoic Acid. Because retinoic acid is the product of catalyzing aldehyde dehydrogenase, we incubated A549 cells with different ATRA concentrations and for different periods of time using 1 or 2 µM ATRA to test a possible negative feedback effect of high levels of retinoic acid on ALDH expression. The effect was measured by enzyme activity and Western and Northern analysis.

Figure 1 shows a dose-response effect on ALDH enzyme activity using ATRA 10-10 to 10-5 M. Because 10-6 M corresponds to the concentration achievable by pharmacologic doses of ATRA, we used that concentration in subsequent experiments. A time-course experiment revealed that ALDH enzyme activity decreases as early as 12 h after the beginning of incubation with 1 µM ATRA and continues as long as 8 days. The persistent decrease in ALDH activity depends on the addition of fresh ATRA every 48 h; otherwise, a rebound of ALDH activity is seen about 72 to 96 h after the initial addition of a single ATRA dose to the cell culture (data not shown). Also, in one experiment, we screened 13-cis and 9-cis retinoic acids for the longer incubation up to 8 days. Similar effects to that of ATRA on ALDH activity were seen by these two retinoic acids. Because of that, subsequent experiments were done with ATRA only. Table 1 and Fig. 2 show a significant decrease in ALDH activity and protein, respectively. Both ALDH-1A1 and ALDH-3A1 proteins are similarly affected on different days of the incubation (Fig. 2). Furthermore, the removal of ATRA after only a 3-h incubation will still result in a significant decrease in ALDH activity (20 ± 3%) at 48 h of continued culture of A549 cells, indicating that the ATRA effect is mediated through retinoic acid receptors and its signal transduction pathways.



View larger version (10K):
[in this window]
[in a new window]
 
Fig. 1. ATRA dose-response effect on ALDH enzyme activity in A549 cells. Each point on the curve represents the mean value for the proportion (percentage) of remaining ALDH activity compared with untreated cells after a 72-h incubation with ATRA. The decrease in activity was highly significant in all ATRA concentrations used (P < 0.005).

 

View this table:
[in this window]
[in a new window]
 
TABLE 1 Effect of retinoic acid on ALDH activity in A549 lung cancer cells

Values represent the mean ± S.D. of the percentage of decrease in ALDH activity in cells treated with retinoic acid (10-6 M) compared with untreated A549 cancer cells. The results of days 5 and 8 for 13-cis retinoic acid reflect the mean ± S.D. of four readings from one experiment. In each raw experiment, the top value is calculated based on activity measured as nanomoles per milligram of protein per minute, whereas the bottom value is calculated based on activity measured as nanomoles per 107 cells/min; n, number of experiments.

 


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 2. Western blot analysis showing a decrease in ALDH-1A1 and ALDH-3A1 proteins at different time points of incubation of A549 cells with 10-6 M ATRA. ATRA was added every 48 h for continued effect. Control (C) A549 cells were treated with an equivalent volume of ethanol because it was used to dissolve the ATRA.

 

Northern analysis of RNA obtained from A549 cells after a 72-h incubation with 1 µM ATRA showed no change in ALDH-1A1 or ALDH-3A1 mRNA levels (data not shown). These results suggest that the ATRA effect on ALDH levels is through post-translational regulatory mechanisms. During ATRA incubation, cell viability and count were determined at different times. A minimal effect on viability was noticed over an 8-day incubation (Fig. 3); however, a significant decrease in proliferation was noticed after a 5-day incubation with ATRA, as reflected by low cell counts compared with untreated cells (Fig. 4).



View larger version (11K):
[in this window]
[in a new window]
 
Fig. 3. Effect of ATRA incubation on A549 cell viability. 105 cells/experimental group were incubated with (dark bars) or without (light bars) 10-6 M ATRA for 3, 5, and 8 days. Cell viability was determined by trypan blue exclusion criteria. Each bar represents mean ± S.D. of viability measured in at least three similar experiments.

 


View larger version (9K):
[in this window]
[in a new window]
 
Fig. 4. Effect of ATRA on A549 cell proliferation as reflected by the -fold increase of total viable cells over time. 105 cells/group were incubated with (dark bars) or without (light bars) 10-6 M ATRA for 3, 5, and 8 days. Cell count and viability was determined at each time point, and the -fold increase in viable cell number was assessed in comparison with the starting cell number. Each bar represents mean ± S.D. of the -fold increase in cell number from at least three different experiments. The differences between the ATRA and the control groups were significant on days 5 and 8 of incubation (P < 0.025).

 

The use of other commercially available retinoic acids such as 13-cis and 9-cis retinoic acids resulted in similar effects to that of ATRA on ALDH enzyme activity in A549 cells (Table 1). Only one screening experiment with 13-cis retinoic acid was performed over 3, 5, and 8 days, and the results in Table 1 show similar but less robust effect on ALDH enzyme activity to that seen with ATRA. Subsequently, and in view of similar results obtained from 72-h incubations with the three different retinoic acids, we focused on performing studies using ATRA only.

To investigate whether the ATRA-induced decrease in ALDH activity is limited to the NSCLC A549 cell line, two other cell lines, NSCLC cell line ADLC-5M2 and small cell lung cancer cell line SW 210.5, were similarly incubated with ATRA for 72 h, and again, significant inhibition (P < 0.05) of ALDH activity was seen (Fig. 5), although the basal activity of ALDH in these cell lines was much lower than that in A549 cells.



View larger version (7K):
[in this window]
[in a new window]
 
Fig. 5. Effect of ATRA incubation on ALDH enzyme activity in two different lung cancer cell lines.

 

Retinoic Acid Preincubation Results in Increased Sensitivity to 4-HC. Preincubation of A549 cells with 1 µM of ATRA or 13-cis or 9-cis retinoic acids for 3 days before treatment with 40 to 80 µg/ml 4-HC (Fig. 6, A) results in a significant increase in 4-HC toxicity (measured by LDH cytotoxicity assay) when compared with control cells. The percentage of release of LDH from the cells in the different groups before any 4-HC treatment was not different among the four experimental groups, indicating no significant toxicity caused by the retinoids themselves. Figure 6B shows a similar increase in 4-HC toxicity against A549 cells, as measured by liquid colony assay. To verify whether such an effect on 4-HC sensitivity correlates specifically to the decrease in ALDH enzyme activity, we treated A549 cells with a different ATRA concentration for 72 h and then with 80 µg/ml 4-HC. As expected, the results show that the increase in 4-HC cytotoxicity (as reflected by the relative amount of LDH release) corresponds to the degree of suppression of ALDH enzyme activity by the different ATRA dose level (Fig. 7, A and B). Furthermore, longer incubation (5 and 8 days) with ATRA or 13-cis retinoic acid does not generally result in more pronounced 4-HC toxicity (Table 2); rather, a plateau effect is seen. The LDH release at 0 µg/ml 4-HC was minimal and not significantly different between the cells in the three treatment groups in Table 2 (similar to what is shown in Fig. 6A), even after 8 days of incubation.



View larger version (19K):
[in this window]
[in a new window]
 
Fig. 6. Two different assays showing the effect of ATRA on 4-HC toxicity. A, LDH cytotoxicity assay, effect of a 72-h preincubation with different retinoic acids (at a concentration of 10-6 M) on 4-HC toxicity against A549 cells. After incubation with ATRA (checked bar), 13-cis retinoic acid (clear bar), or 9-cis retinoic acid (black bar), cells were treated with either 0, 40, or 80 µg/ml 4-HC as described under Materials and Methods, and then, 24 h later, LDH cytotoxicity assay was performed to determine 4-HC toxicity. The percentage of release of LDH from the 0-µg/ml 4-HC treatment groups was calculated in relation to the LDH readings in the culture medium only. B, liquid colony assay, after a 72-h incubation with (black bar) or without 10-6 M ATRA and treatment with 4-HC, A549 cells were washed two times and plated at 2.5-104 cells/ml/plate, using RPMI culture medium plus 10% FBS. Adhered colonies were scored on day 4. The results reflect the recovery of colonies after 4-HC treatment as a percentage of the number of colonies counted from the same number of untreated cells. Untreated ATRA and control cells had a similar (mean ± S.D.) number of colonies obtained from plating 200 cells/ml/plate (47 ± 10 and 47 ± 9, respectively).

 


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 7. Effect of ATRA concentrations on ALDH enzyme activity (A) and the effect on 4-HC toxicity (B) in A549 cells. 5 x 105 cells/experimental group were incubated with ATRA for 72 h, and then cells were treated with 4-HC (80 µg/ml) as described under Materials and Methods. LDH cytotoxicity assay was performed 24 h later. The results reflect mean ± S.D. of three different experiments. The increase in 4-HC toxicity was significant only after incubation with 10-7 and 10-6 M ATRA (P < 0.01).

 

View this table:
[in this window]
[in a new window]
 
TABLE 2 Effect of preincubation of A549 lung cancer cells with retinoids on 4-HC toxicity

A549 cells were incubated with or without 10–6M ATRA or 13-cis retinoic acid for 3, 5, and 8 days, and then 105 cells/group were treated with 4-HC (40 and 80 µg/ml) for 30 min at 37°C. Cells were then washed twice and plated in liquid culture. LDH cytotoxicity assay was performed 24 h later to determine 4-HC toxicity. The values given reflect the mean ± S.D. of the percentage of toxicity from at least two different experiments (three readings per each experiment) for ATRA and only one for 13-cis retinoic acid. There was no significant difference in LDH release between the three groups at 0 µg/ml 4-HC, even after 8 days of incubation.

 

On the other hand, we used other cytotoxic drugs that are not metabolized by aldehyde dehydrogenase, such as PKP and melphalan, to further investigate the specificity of the retinoic acid effect. Table 3 shows that a 72-h ATRA preincubation results in increased cytotoxicity of PKP and melphalan but to a lesser degree than that seen for 4-HC.


View this table:
[in this window]
[in a new window]
 
TABLE 3 Effect of ATRA preincubation on PKP and melphalan toxicity against A549 cells compared with that of 4-HC

ATRA was preincubated for 72 h and then treated with either PKP (60 µg/ml), melphalan (60 µM), or 4-HC (80 µg/ml). Cytotoxicity (percentage of LDH release) was measured about 24 h after the treatment with the chemotherapeutic agents. The values shown reflect mean ± S.D. of at least six experiments.

 

The other two cell lines, ADLC-5M2 and SW210.5, were similarly treated with ATRA and 4-HC. Toxicity was measured by LDH cytotoxicity assay. The results showed increased sensitivity to 80 µg/ml 4-HC toxicity by 23 to 50% over that seen with the control cells with no prior ATRA incubation.

Increased Acetaldehyde Cytotoxicity after ATRA Incubation. Because of the use of carotinoid derivatives in cancer prevention and because acetaldehyde is a known carcinogen metabolized by ALDH, we examined the effects of the ATRA-induced decrease in ALDH enzyme activity on the cytotoxicity of acetaldehyde. Figure 8A shows partial results of the dose-dependent toxicity against A549 cells after a 24-h exposure to acetaldehyde. Doses of 200, 400, and 800 µM had zero toxicity. Figure 8B shows significant (P < 0.025) increase in the cytotoxic effects of acetaldehyde (20 mM for 24 h) on A549 cells after a 72-h incubation with any of the three retinoic acids used here.



View larger version (14K):
[in this window]
[in a new window]
 
Fig. 8. A, acetaldehyde dose-dependent cytotoxicity against A549 cells. 5 x 105 cells/experimental group were treated for 24 h with varying doses of acetaldehyde, and toxicity was measured by LDH cytotoxicity assay. B, effect of ATRA preincubation on the sensitivity of A549 cells to acetaldehyde (20 mM/24 h). 5 x 105 cells/experimental group were incubated with 10-6 M of either ATRA (black bar), 13-cis RA (dark gray bar), 9-cis RA (clear bar), or just culture medium (control) (light gray bar) for 72 h, and then 105 cells of each group were incubated with 20 mM acetaldehyde for 24 h. Toxicity was measured by LDH cytotoxicity assay, and the results were expressed as mean ± S.D. of three similar experiments. See Fig. 6 for LDH release from cells in the four groups prior to acetaldehyde treatment. All differences between the treatment groups and control group shown in this figure were highly significant, with P < 0.025.

 

Although the concentrations of acetaldehyde used here seem very high, it is important to know that A549 cells are relatively resistant and that treatment with 5 to 20 mM acetaldehyde for 24 h is 100% lethal to an immortalized normal epithelial cell line, IB-3 (Flotte et al., 1992Go), that has minimal ALDH activity (data not shown).


    Discussion
 Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 
ALDH-1A1 has been shown to catalyze retinaldehyde into retinoic acid in several tissues (Lee et al., 1991Go; Yoshida et al., 1992Go; Gudas et al., 1994Go; Bhat et al., 1995Go; Means and Gudas, 1995Go; Chytil, 1996Go; Hsu et al., 1999Go). In this report, we show that incubation of lung cancer cell lines with any of three different retinoic acids results in a significant decrease in ALDH-1A1 and ALDH-3A1 protein and enzyme activity. The decrease seems to take place at the post-translational level since retinoic acid did not affect the mRNA levels for both enzymes. Although a significant decrease in ALDH activity is seen with very low retinoic acid concentrations of 10-10 M, further dose escalation did not show a significant drop in activity until toxic ATRA concentrations of 10-5 M. These observations are significant since a 10-5 M concentration of ATRA is clinically unattainable and unfeasible. Furthermore, it seems that the decrease in ALDH activity is significant with a wide range of ATRA concentrations. Using a therapeutic concentration of ATRA (1-2 x 10-6 M) over 8 days shows that the decrease in ALDH enzyme activity occurs as early as 12 h after the initiation of retinoic acid exposure and continues to drop as late as 8 days, but the best and most consistent effect on 4-HC cell sensitivity seems to be between days 3 to 5 of retinoic acid incubation. Such a plateau effect on the 4-HC sensitivity could be related to other compensatory mechanisms or an artifact of the culture system.

The viability data (Fig. 3) show minimal direct toxicity by ATRA itself but more pronounced inhibition of proliferation (Fig. 4). This observation suggests a possible cell cycle inhibition during prolonged incubation with ATRA. These ATRA effects that may vary from one cell type to another have been described and published previously (Sun et al., 1999Go; Lutz et al., 2001Go; Sun and Lotan, 2002Go; Hayashi et al., 2003Go). It is possible that the above-mentioned plateau effect on 4-HC toxicity beyond 5 days of continuous incubation with ATRA is associated to such proliferation inhibition.

We believe that this is the first report to describe a mechanism by which retinoic acid may enhance the efficacy of a chemotherapeutic agent such as 4-HC. However, few previous studies reported such effects of retinoic acid on other cytotoxic drugs, including cisplatin, etoposide, paclitaxel, and gemcitabine (Formelli and Cleris, 1993Go; Shalinsky et al., 1996Go; Grunt et al., 1998Go; Kalemkerian and Ou, 1999Go; Pettersson et al., 2001Go). The basis for those studies was the known antitumor effects of retinoic acids. Thus, it was important to study the specificity of the ATRA-induced enhancement of the cytotoxic effects of 4-HC against A549 cells. Our studies show that ATRA preincubation results in increased sensitivity to melphalan and PKP, both of which are not metabolized by ALDH-1 or ALDH-3, but to a much lesser degree than that seen with 4-HC. Thus, ATRA or other retinoic acids seem to have an additional yet unknown effect other than that on ALDH. These results are not surprising because retinoids have been known for years as potent agents that control cellular proliferation, differentiation, and apoptosis through a wide array of signal transduction pathways.

Acetaldehyde is a known carcinogenic aldehyde that could be found in cigarette or car exhaust smoke as well as a product of ethanol metabolism. Acetaldehyde plays an important role in the pathogenesis of tissue injury that results from alcohol and cigarette consumption (Feron et al., 1991Go; Koivisto and Salaspuro, 1997Go). Since acetaldehyde is a substrate for aldehyde dehydrogenase, the presence of high levels of ALDH could protect against the toxicity of acetaldehyde, and vice versa. Our studies show that the ATRA-induced reduction in ALDH-1A1 and ALDH-3A1 results in increased acetaldehyde toxicity. Similar interaction was reported between {beta}-carotene and acetaldehyde and was attributed to the common metabolic pathway, possibly via ALDH (Ni et al., 2001Go).

Our current results should open the way to new studies that further evaluate the regulatory mechanisms involved in the retinoic acid-induced reduction in ALDH-1A1/ALDH-3A1 levels. The fact that the ALDH-1A1/ALDH-3A1 mRNA's were not reduced by ATRA indicates a possible post-translational mechanism that results in decreased protein levels and enzyme activity of these isozymes. It is possible that our initial hypothesis about a retinoic acid-mediated negative feedback might be true, but the possibility that ALDH inhibition may be induced indirectly through another retinoic acid-known biological effect seems more likely, and further investigation will be needed. Indeed, retinoic acid was reported to reduce p11 protein (Gladwin et al., 2000Go), cyclin D1 (Langenfeld et al., 1997Go), and retinoic acid receptors {alpha} and {beta} by inducing degradation through the ubiquitin-proteasome pathway, a post-translational mechanism. Thus, it is possible that ALDH-1A1 and ALDH-3A1 are also regulated by proteolysis through the ubiquitin-proteasome system or other mechanisms and that the retinoic acid effect on their levels is mediated through increased protein degradation.

In summary, we have shown that different forms of retinoic acids reduce the ALDH-1A1 and ALDH-3A1 proteins and enzyme activity via a post-translational mechanism and increase the cytotoxicity of 4-HC and acetaldehyde in lung cancer cell lines. Based on these observations, it will be reasonable to pursue clinical trials combining ATRA and cyclophosphamide in the treatment of lung cancer and other malignancies. Furthermore, our observations could serve as the basis for studying and revealing the regulatory mechanisms involved in determining the cellular expression of these enzymes.


    Footnotes
 
Financial support for this work was provided by grants (to J.S.M.) from the American Lung Association of Florida (Jacksonville, FL) and the Flight Attendant Medical Research Institute (Miami, FL).

doi:10.1124/jpet.104.072496.

ABBREVIATIONS: ALDH, aldehyde dehydrogenase(s); ALDH-1A1, aldehyde dehydrogenase class 1A1; ALDH-3A1, aldehyde dehydrogenase class 3A1; 4-HC, 4-hyroperoxycyclophosphamide; RA, retinoic acid; NSCLC, nonsmall cell lung cancer; FBS, fetal bovine serum; ATRA, all-trans retinoic acid; PKP, phenylketophosphamide; LDH, lactose dehydrogenase.

Address correspondence to: Dr. Jan S. Moreb, University of Florida, College of Medicine, Department of Medicine, Division of Hematology/Oncology, P.O. Box 100277, 1600 SW Archer Road, Room R4-220, Gainesville, FL 32610-0277. E-mail: morebjs{at}medicine.ufl.edu


    References
 Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 

Bepler G, Bading H, Heimann B, Kiefer P, Havemann K, and Moelling K (1989) Expression of p64c-myc and neuroendocrine properties define three subclasses of small cell lung cancer. Oncogene 4: 45-50.[Medline]

Bepler G, Koehler A, Kiefer P, Havemann K, Beisenherz K, Jaques G, Gropp C, and Haeder M (1988) Characterization of the state of differentiation of six newly established human non-small-cell lung cancer cell lines. Differentiation 37: 158-171.[CrossRef][Medline]

Bhat PV, Labrecque J, Boutin JM, Lacroix A, and Yoshida A (1995) Cloning of a cDNA encoding rat aldehyde dehydrogenase with high activity for retinal oxidation. Gene 166: 303-306.[CrossRef][Medline]

Bunting KD, Lindahl R, and Townsend AJ (1994) Oxazaphosphorine-specific resistance in human MCF-7 breast carcinoma cell lines expressing transfected rat class 3 aldehyde dehydrogenase. J Biol Chem 269: 23197-23203.[Abstract/Free Full Text]

Bunting KD and Townsend AJ (1996) De novo expression of transfected human class 1 aldehyde dehydrogenase (ALDH) causes resistance to oxazaphosphorine anticancer alkylating agents in hamster V79 cell lines. Elevated class 1 ALDH activity is closely correlated with reduction in DNA interstrand cross-linking and lethality. J Biol Chem 271: 11884-11890.[Abstract/Free Full Text]

Chomczynski P and Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159.[Medline]

Chytil F (1996) Retinoids in lung development. FASEB J 10: 986-992.[Abstract]

Feron VJ, Til HP, de Vrijer F, Woutersen RA, Cassee FR, and van Bladeren PJ (1991) Aldehydes: occurrence, carcinogenic potential, mechanism of action and risk assessment. Mutat Res 259: 363-385.[CrossRef][Medline]

Flotte TR, Solow R, Owens RA, Afione S, Zeitlin PL, and Carter BJ (1992) Gene expression from adeno-associated virus vectors in airway epithelial cells. Am J Respir Cell Mol Biol 7: 349-356.

Formelli F and Cleris L (1993) Synthetic retinoid fenretinide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity. Cancer Res 53: 5374-5376.[Abstract/Free Full Text]

Gladwin MT, Yao XL, Cowan M, Huang XL, Schneider R, Grant LR, Logun C, and Shelhamer JH (2000) Retinoic acid reduces p11 protein levels in bronchial epithelial cells by a posttranslational mechanism. Am J Physiol Lung Cell Mol Physiol 279: L1103-L1109.[Abstract/Free Full Text]

Grunt T, Dittrich E, Offterdinger M, Schneider SM, Dittrich C, and Huber H (1998) Effects of retinoic acid and fenretinide on the c-erbB-2 expression, growth and cisplatin sensitivity of breast cancer cells. Br J Cancer 78: 79-87.[Medline]

Gudas LJ, Sporn MB, and Roberts AB (1994) Cellular biology and biochemistry of retinoids, in The Retinoids (Sporn MB, Roberts AB, and Goodman DS eds) pp 443-520, Raven Press, New York.

Hayashi K, Goodison S, Urquidi V, Tarin D, Lotan R, and Tahara E (2003) Differential effects of retinoic acid on the growth of isogenic metastatic and nonmetastatic breast cancer cell lines and their association with distinct expression of retinoic acid receptor beta isoforms 2 and 4. Int J Oncol 22: 623-629.[Medline]

Hilton J (1984) Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia. Cancer Res 44: 5156-5160.[Abstract/Free Full Text]

Hsu LC, Chang WC, Hoffmann I, and Duester G (1999) Molecular analysis of two closely related mouse aldehyde dehydrogenase genes: identification of a role for Aldh1, but not Aldh-pb, in the biosynthesis of retinoic acid. Biochem J 339 (Pt 2): 387-395.

Kalemkerian GP and Ou X (1999) Activity of fenretinide plus chemotherapeutic agents in small-cell lung cancer cell lines. Cancer Chemother Pharmacol 43: 145-150.[CrossRef][Medline]

Koivisto T and Salaspuro M (1997) Effects of acetaldehyde on brush border enzyme activities in human colon adenocarcinoma cell line Caco-2. Alcohol Clin Exp Res 21: 1599-1605.[CrossRef][Medline]

Langenfeld J, Kiyokawa H, Sekula D, Boyle J, and Dmitrovsky E (1997) Posttranslational regulation of cyclin D1 by retinoic acid: a chemoprevention mechanism. Proc Natl Acad Sci USA 94: 12070-12074.[Abstract/Free Full Text]

Lee MO, Manthey CL, and Sladek NE (1991) Identification of mouse liver aldehyde dehydrogenases that catalyze the oxidation of retinaldehyde to retinoic acid. Biochem Pharmacol 42: 1279-1285.[CrossRef][Medline]

Lutz PG, Houzel-Charavel A, Moog-Lutz C, and Cayre YE (2001) Myeloblastin is a Myb target gene: mechanism of regulation in myeloid leukemia cells growth-arrested by retinoic acid. Blood 97: 2449-2456.[Abstract/Free Full Text]

Magni M, Shammah S, Schiro R, Mellado W, Dalla-Favera R, and Gianni AM (1996) Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer. Blood 87: 1097-1103.[Abstract/Free Full Text]

Manthey CL, Landkamer GJ, and Sladek NE (1990) Identification of the mouse aldehyde dehydrogenases important in aldophosphamide detoxification. Cancer Res 50: 4991-5002.[Abstract/Free Full Text]

Means AL and Gudas LJ (1995) The roles of retinoids in vertebrate development. Annu Rev Biochem 64: 201-233.[CrossRef][Medline]

Moreb J, Schweder M, Suresh A, and Zucali JR (1996) Overexpression of the human aldehyde dehydrogenase class I results in increased resistance to 4-hydroperoxycyclophosphamide. Cancer Gene Ther 3: 24-30.[Medline]

Moreb JS, Maccow C, Schweder M, and Hecomovich J (2000) Expression of antisense RNA to aldehyde dehydrogenase class-1 sensitizes tumor cells to 4-hydroperoxycyclophosphamide in vitro. J Pharmacol Exp Ther 293: 390-396.[Abstract/Free Full Text]

Moreb JS, Schweder M, Gray B, Zucali J, and Zori R (1998) In vitro selection for K562 cells with higher retrovirally mediated copy number of aldehyde dehydrogenase class-1 and higher resistance to 4-hydroperoxycyclophosphamide. Hum Gene Ther 9: 611-619.[Medline]

Ni R, Leo MA, Zhao J, and Lieber CS (2001) Toxicity of beta-carotene and its exacerbation by acetaldehyde in HepG2 cells. Alcohol Alcohol 36: 281-285.[Abstract/Free Full Text]

Pettersson F, Colston KW, and Dalgleish AG (2001) Retinoic acid enhances the cytotoxic effects of gemcitabine and cisplatin in pancreatic adenocarcinoma cells. Pancreas 23: 273-279.[CrossRef][Medline]

Shalinsky DR, Bischoff ED, Gregory ML, Lamph WW, Heyman RA, Hayes JS, Thomazy V, and Davies PJ (1996) Enhanced antitumor efficacy of cisplatin in combination with ALRT1057 (9-cis retinoic acid) in human oral squamous carcinoma xenografts in nude mice. Clin Cancer Res 2: 511-520.[Abstract]

Sladek NE, Kollander R, Sreerama L, and Kiang DT (2002) Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens. Cancer Chemother Pharmacol 49: 309-321.[CrossRef][Medline]

Sreerama L and Sladek NE (1993) Identification and characterization of a novel class 3 aldehyde dehydrogenase overexpressed in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance. Biochem Pharmacol 45: 2487-2505.[CrossRef][Medline]

Sun S-Y, Li W, Yue P, Lippman SM, Hong WK, and Lotan R (1999) Mediation of N-(4-hydrophenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms. Cancer Res 59: 2493-2498.[Abstract/Free Full Text]

Sun S-Y and Lotan R (2002) Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol 41: 41-55.[Medline]

von Eitzen U, Meier-Tackmann D, Agarwal DP, and Goedde HW (1994) Detoxification of cyclophosphamide by human aldehyde dehydrogenase isozymes. Cancer Lett 76: 45-49.[CrossRef][Medline]

Yoshida A, Hsu LC, and Dave V (1992) Retinal oxidation activity and biological role of human cytosolic aldehyde dehydrogenase. Enzyme 46: 239-244.[Medline]

Yoshida A, Rzhetsky A, Hsu LC, and Chang C (1998) Human aldehyde dehydrogenase gene family. Eur J Biochem 251: 549-557.[Medline]


This article has been cited by other articles:


Home page
Hum ReprodHome page
M. Zaitseva, B. J. Vollenhoven, and P. A.W. Rogers
Retinoids regulate genes involved in retinoic acid synthesis and transport in human myometrial and fibroid smooth muscle cells
Hum. Reprod., May 1, 2008; 23(5): 1076 - 1086.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. Visus, D. Ito, A. Amoscato, M. Maciejewska-Franczak, A. Abdelsalem, R. Dhir, D. M. Shin, V. S. Donnenberg, T. L. Whiteside, and A. B. DeLeo
Identification of Human Aldehyde Dehydrogenase 1 Family Member A1 as a Novel CD8+ T-Cell Defined Tumor Antigen in Squamous Cell Carcinoma of the Head and Neck
Cancer Res., November 1, 2007; 67(21): 10538 - 10545.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
M. Yoon, M. C. Madden, and H. A. Barton
Developmental Expression of Aldehyde Dehydrogenase in Rat: a Comparison of Liver and Lung Development
Toxicol. Sci., February 1, 2006; 89(2): 386 - 398.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.104.072496v1
312/1/339    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moreb, J. S.
Right arrow Articles by Mohuczy, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moreb, J. S.
Right arrow Articles by Mohuczy, D.


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition